Urist Marshall
SEC CIK 1838139 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma plc | EVP, Research, Investments | 8,252 | — | $15.88M | 29 | 2022-05-11 | 2026-08-05 |
Most active insiders at RPRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Coyne Terrance P. | EVP, CFO | — | $38.96M |
| 2 | Hite Christopher | EVP, Vice COB | — | $27.36M |
| 3 | Lloyd George W. | EVP, CLO, Investments | — | $13.81M |
| 4 | Urist Marshall | EVP, Research, Investments | — | $12.07M |
| 5 | Norden Gregory | Dir | — | $161.4K |
| 6 | Engelbert Catherine M. | Dir | — | — |
| 7 | Ho Carole | Dir | — | — |
| 8 | Coric Vlad | Dir | — | — |
| 9 | Bassler Bonnie L | Dir | — | — |
| 10 | Legorreta Pablo G. | CEO, COB, Dir | — | — |
Transactions 29
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 17:11 | 2026-08-05 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +8,252 | 8,252 | New | $0 |
| T | 2026-07-02 16:10 | 2026-07-01 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $55.88 | -9,099 | 0 | -100% | -$508.5K |
| T | 2026-06-25 17:13 | 2026-06-24 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $55.18 | -9,098 | 9,099 | -50% | -$502.1K |
| T | 2026-05-21 21:20 | 2026-05-20 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $52.75 | -13.7K | 18.2K | -43% | -$721.8K |
| T | 2026-05-15 16:38 | 2026-05-14 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $53.06 | -13.7K | 31.9K | -30% | -$726.1K |
| 2026-05-08 17:10 | 2026-05-06 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +18.2K | 45.6K | +66% | $0 | |
| 2026-02-13 | 2026-02-11 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +20.0K | 27.4K | +270% | $0 | |
| I | 2026-02-02 | 2026-01-30 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $41.09 | -20.0K | 0 | -100% | -$821.8K |
| I | 2026-01-26 | 2026-01-23 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $40.26 | -20.0K | 20.0K | -50% | -$805.2K |
| I | 2026-01-20 | 2026-01-16 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.52 | -20.0K | 40.0K | -33% | -$790.4K |
| I | 2026-01-13 | 2026-01-09 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $40.78 | -20.0K | 60.0K | -25% | -$815.6K |
| I | 2026-01-06 | 2026-01-02 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.48 | -20.0K | 80.0K | -20% | -$769.6K |
| I | 2025-12-29 | 2025-12-26 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.32 | -20.0K | 100.0K | -17% | -$786.4K |
| I | 2025-12-22 | 2025-12-19 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.38 | -20.0K | 120.0K | -14% | -$767.6K |
| I | 2025-12-17 | 2025-12-16 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.32 | -20.0K | 140.0K | -12% | -$766.4K |
| I | 2025-12-09 | 2025-12-05 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.15 | -23.3K | 160.0K | -13% | -$913.5K |
| 2025-12-09 | 2025-12-05 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.15 | -18.2K | 7,398 | -71% | -$714.2K | |
| 2025-12-03 | 2025-12-01 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.90 | -18.2K | 25.6K | -42% | -$727.9K | |
| I | 2025-12-03 | 2025-12-01 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.93 | -23.3K | 183.3K | -11% | -$931.7K |
| DI | 2025-11-07 | 2025-11-07 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | C - Cnv Deriv | $0.00 | +160.0K | 206.7K | +343% | $0 |
| D | 2025-11-07 | 2025-11-05 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +4,626 | 43.9K | +12% | $0 |
| D | 2025-08-08 | 2025-08-06 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +2,772 | 39.3K | +8% | $0 |
| 2025-05-09 | 2025-05-08 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +36.5K | 83.2K | +78% | $0 | |
| 2023-02-24 | 2023-02-22 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $37.30 | -23.3K | 46.7K | -33% | -$870.3K | |
| D | 2023-02-17 | 2023-02-17 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | C - Cnv Deriv | $0.00 | +70.0K | 70.0K | New | $0 |
| M | 2022-07-27 | 2022-07-25+ | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $43.18 | -23.3K | 0 | -100% | -$1.01M |
| 2022-06-24 | 2022-06-24 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $43.19 | -23.3K | 23.3K | -50% | -$1.01M | |
| 2022-05-16 | 2022-05-16 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.85 | -23.3K | 46.7K | -33% | -$929.8K | |
| D | 2022-05-11 | 2022-05-11 | RPRX | Royalty Pharma plc | Urist Marshall | EVP, Research, Investments | C - Cnv Deriv | $0.00 | +70.0K | 70.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations